Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2473921 | 0.94 | POLB (0.33) | MEN1POLBKMT2A | |
| SCHEMBL29430049 | 0.88 | OR51E2 (0.30) | MEN1POLBKMT2AGAAMAPK1 | |
| SCHEMBL29430046 | 0.85 | OR51E2 (0.31) | GRIN1GRIN2AMEN1POLBKMT2A | |
| SCHEMBL19398306 | 0.83 | HSD11B1 (0.35) | GRIN1GRIN2AGRIN2BPOLBKMT2A | |
| SCHEMBL19398304 | 0.83 | HSD11B1 (0.35) | GRIN1GRIN2AGRIN2BPOLBKMT2A | |
| SCHEMBL12700561 | 0.79 | SIGMAR1 (0.33) | — | |
| SCHEMBL8203601 | 0.74 | — | — | |
| SCHEMBL20807986 | 0.73 | CRBN (0.44) | — | |
| SCHEMBL22510980 | 0.72 | GAA (0.36) | GAA | |
| SCHEMBL31580548 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591328-B2 | Highly active CSF1R inhibitor compound | XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20200399265-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2020-12-24 | — | — | US | disclosed |
| EP-3744718-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019228252-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | 杭州阿诺生物医药科技有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591328-B2 | Highly active CSF1R inhibitor compound | CSF1R, CSF3R, CD209 | GRIN1 184/4885GRIN2A 664/4885GRIN2B 390/4885 |
| US-20200399265-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | CSF1R, CSF3R, CD209 | GRIN1 184/4885GRIN2A 664/4885GRIN2B 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.